The participation of HPV-vaccinated women in a national cervical screening program: Population-based cohort study

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Herweijer, Eva ^a   Feldman, Adina L ^a,b   Ploner, Alexander ^a   Arnheim Dahlström, Lisen ^a   Uhnoo, Ingrid ^c   Netterlid, Eva ^c,d,e   Dillner, Joakim ^a   Sparén, Pär ^a   Sundström, Karin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; EDUCATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH PROGRAM; HUMAN; INCOME; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PROPORTIONAL HAZARDS MODEL; SCREENING; SENSITIVITY ANALYSIS; SMEAR; SWEDEN; UTERINE CERVIX; UTERINE CERVIX CANCER; VACCINATION; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT PARTICIPATION; PHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; UTERINE CERVICAL NEOPLASMS; UTILIZATION; VIROLOGY; YOUNG ADULT;

ADULT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT PARTICIPATION; PROGNOSIS; SWEDEN; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84941624979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134185     Document Type: Article

References (24)

1. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: A Swedish national cohort study. J Natl Cancer Inst 2013; 105: 469-74. doi: 10.1093/jnci/djt032 PMID: 23486550
2. Socialstyrelsen. [Regulations from the National Board of Health and Welfare concerning changes in regulations (SOSFS 2006: 22) concerning vaccination of children. SOSFS 2008: 31.], 2008.
3. Sundström K, Tran TN, Lundholm C, Young C, Sparen P, Dahlström LA. Acceptability of HPV vaccination among young adults aged 18-30 years-A population based survey in Sweden. Vaccine 2010; 28: 7492-500. doi: 10.1016/j.vaccine.2010.09.007 PMID: 20851088
4. Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. Jama 2014; 311: 597-603. doi: 10.1001/jama.2014.95 PMID: 24519299
5. Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: Population based cohort study. Bmj 2012; 344: E900. doi: 10.1136/bmj.e900 PMID: 22381677
6. [Cervical screening in Sweden. Annual report 2013 from the National Quality Register for Cervical Cancer Prevention.] In Swedish. In: Dillner J, ed., 2013.
7. Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. International journal of cancer Journal international du cancer 2011; 129: 2632-42. doi: 10.1002/ijc.25940 PMID: 21491420
8. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-Associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-39. doi: 10.1093/jnci/djp534 PMID: 20139221
9. Elfstrom KM, Herweijer E, Sundstrom K, Arnheim-Dahlstrom L. Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: A review. Curr Opin Oncol 2014; 26: 120-9. doi: 10.1097/CCO.0000000000000034 PMID: 24248011
10. Kulasingam SL, Pagliusi S, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: An example from the U.S. Vaccine 2007; 25: 8110-3. PMID: 17961877
11. Mather T, McCaffery K, Juraskova I. Does HPV vaccination affect women's attitudes to cervical cancer screening and safe sexual behaviour? Vaccine 2012; 30: 3196-201. doi: 10.1016/j.vaccine.2012.02. 081 PMID: 22425789
12. Juraskova I, Bari RA, O'Brien MT, McCaffery KJ. HPV vaccine promotion: Does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior? Womens Health Issues 2011; 21: 71-9. doi: 10.1016/j.whi.2010.08.004 PMID: 21185992
13. Bowyer HL, Marlow LA, Hibbitts S, Pollock KG, Waller J. Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England. Vaccine 2013; 31: 1051-6. doi: 10.1016/j.vaccine.2012.12.038 PMID: 23277094
14. Cooper Robbins SC, Bernard D, McCaffery K, Brotherton J, Garland S, Skinner SR. "Is cancer contagious?": Australian adolescent girls and their parents: Making the most of limited information about HPV and HPV vaccination. Vaccine 2010; 28: 3398-408. doi: 10.1016/j.vaccine.2010.02.078 PMID: 20199758
15. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-67. doi: 10.1007/s10654-009-9350-y PMID: 19504049
16. Folkhälsomyndigheten. [Public Health Agency of Sweden: Description of the Swedish Vaccination Register (SVEVAC)]. Secondary [Public Health Agency of Sweden: Description of the Swedish Vaccination Register (SVEVAC)] 2014. Available: Http://www.folkhalsomyndigheten.se/amnesomraden/smittskydd-och-sjukdomar/vaccinationer/svevac/.
17. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35. PMID: 16897791
18. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974; 19: 716-23.
19. Schoenfeld D. Partial residuals for the proportional hazards model. Biometrika 1982; 69: 239-41.
20. Bowyer HL, Dodd RH, Marlow LA, Waller J. Association between human papillomavirus vaccine status and other cervical cancer risk factors. Vaccine 2014; 32(34): 4310-6. doi: 10.1016/j.vaccine.2014.06. 011 PMID: 24950359
21. Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK? Vaccine 2014; 32: 1828-33. doi: 10.1016/j.vaccine.2014.01.087 PMID: 24530938
22. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106: Djt460. doi: 10.1093/jnci/djt460 PMID: 24552678
23. Sauer AG, Jemal A, Simard EP, Fedewa SA. Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008-2013. Cancer Epidemiol. 2015 Jun 5. pii: S1877-7821(15)00101-0. doi: 10.1016/j.canep.2015.05.002. [Epub ahead of print].
24. Budd AC, Brotherton JM, Gertig DM, Chau T, Drennan KT, Saville M. Cervical screening rates for women vaccinated against human papillomavirus. Med J Aust 2014; 201: 279-82. PMID: 25163380